Shares of psychedelic drug developers rise premarket after U.S. President Donald Trump signed an executive order on Saturday, telling health regulators to speed up review of psychedelic drugs such as ibogaine and set aside $50 million for research
Shares of Atai (ATAI.O) jump 21%, Definium Therapeutics (DFTX.O) rise 18%, Compass Pathways (CMPS.O) climb 24%, GH Research (GHRS.O) gain 19%, Enveric (ENVB.O) add 7% before the bell
U.S.-listed shares of Cybin (HELP.O) up 15%
Brokerage Jefferies says the order is an “official stamp of validation to the class”, showing government support is “real/actionable (not rhetorical)”
Ibogaine is a naturally occurring psychoactive compound derived from an African shrub that is being studied as a potential treatment for addiction and mental health disorders
Psychedelic drugs with Breakthrough Therapy Designation may get Commissioner National Priority Review Vouchers, cutting FDA review from 6-10 month review time down to 1-2 months, Jefferies noted

ATAI

CMPS

DFTX

PSIL

- Former U.S. President Donald Trump signed an executive order to accelerate the review of psychedelic drugs like ibogaine and allocated $50 million for research, boosting stock prices for relevant companies.  
- Stocks of Atai, Definium Therapeutics, Compass Pathways, GH Research, Enveric, and Cybin saw significant pre-market gains following the announcement.  
- The order represents a formal acknowledgment of support for the category, indicating that government backing is tangible, potentially leading to expedited FDA reviews for breakthrough treatments.

BUZZ-Psychedelic drug developers rise after Trump signals regulatory support